Current role of ceftobiprole in the treatment of hospital-acquired and community-acquired pneumonia: Expert opinion based on literature and real-life experiences

Expert Review of Anti-infective Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Community-acquired pneumonia (CAP) and hospital-acquired (HAP) are major global health challenges, with high morbidity mortality rates. The increasing prevalence of multidrug-resistant (MDR) bacteria may diminish the effectiveness standard empirical antibiotics, highlighting need for broader-spectrum agents that target also MDR organisms. This review summarizes findings from a PubMed search on use ceftobiprole in CAP HAP. It highlights key features ceftobiprole, including its mechanism action broad spectrum activity against multiple pathogens. Clinical data randomized controlled trials real-world studies underscore non-inferiority to treatments, favorable safety profile clinical cure rates even challenging cases. Ceftobiprole represents valid option patients Its main advantages include activity, making it valuable therapeutic choice treating polymicrobial infections, profile, which makes good candidate elderly comorbidities polypharmacy. Caution is advised at risk ESBL-producing organisms or Pseudomonas aeruginosa where combination therapy recommended. Moreover, drug monitoring recommended improve outcomes, particularly complex conditions.

Language: Английский

---

Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?

Pathogens, Journal Year: 2024, Volume and Issue: 13(1), P. 88 - 88

Published: Jan. 19, 2024

Antibiotic resistance in Gram-positive pathogens is a relevant concern, particularly the hospital setting. Several antibiotics are now available to treat these drug-resistant pathogens, such as daptomycin, dalbavancin, linezolid, tedizolid, ceftaroline, ceftobiprole, and fosfomycin. However, antibiotic can also affect newer molecules. Overall, this not frequent phenomenon, but it growing concern some settings compromise effectiveness of molecules, leaving few therapeutic options. We reviewed evidence about epidemiology main molecular mechanisms resistance, methicillin-resistant Sthaphylococcus aureus, coagulase-negative staphylococci, vancomycin-resistant Enterococcus faecium, penicillin-resistant Streptococcus pneumoniae. discussed interpretation susceptibility tests when minimum inhibitory concentrations available. focused on risk emergence during treatment, for daptomycin fosfomycin, we strategies that be implemented reduce which lead clinical failure despite appropriate treatment. The judicious use antibiotics, epidemiological surveillance, infection control measures essential preserving efficacy drugs.

Language: Английский

---

Real-World Experience of Ceftobiprole for Community- and Hospital-Acquired Pneumonia from a Stewardship Perspective

Microorganisms, Journal Year: 2024, Volume and Issue: 12(4), P. 725 - 725

Published: April 3, 2024

Ceftobiprole is a fifth-generation cephalosporin approved by European and American regulatory agencies for the treatment of community-acquired pneumonia (CAP) hospital-acquired (HAP). administration useful in severe CAP as well HAP where potential to save other β-lactams including carbapenems or linezolid/vancomycin clinical practice. The aim this study was report real-world evidence ceftobiprole patients with single center. In retrospective study, we included 159 HAP: 105 (66%) had 54 (34%) HAP. median age 70 years (IQR 60–77), Charlson Comorbidity Index 5 3–7.5) baseline INCREMENT ESBL score 8 6–11). mostly given combination (77%) carbapenem-sparing strategy (44%). There were no differences mortality between shorter longer duration (<7 days compared ≥7 (HR 1.02, C.I. 0.58–1.77, p = 0.93) first-line 1.00, 0.46–2.17, 0.989) second-line therapy. use real world effective first- strategy. Further studies are needed explore full ceftobiprole, its antimicrobial stewardship programs.

Language: Английский

---

Ceftobiprole medocaril for skin and skin-structure infections

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: March 3, 2025

Introduction On 3 April 2024, the United States Food and Drug Administration (FDA) approved ceftobiprole medocaril sodium (Zevtera) for injection treatment of adults with acute bacterial skin structure infections (ABSSSI) as well patients Staphylococcus aureus bloodstream three months to less than 18 years old community-acquired pneumonia.

Language: Английский

---

Management of methicillin-resistant staphylococcus aureus bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges ahead

Expert Review of Anti-infective Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 31, 2025

Bloodstream infections (BSIs) caused by Staphylococcus aureus are common worldwide, representing one of the most relevant issues in clinical infectious diseases practice. In particular, BSIs methicillin-resistant S. (MRSA-BSI) still today a challenge since mortality burden remains elevated although decades research. The following topics regarding MRSA-BSI were reviewed and discussed resorting to best available evidence retrieved from PubMed/MEDLINE up October 2024: i) epidemiology; ii) microbiology; iii) classification, with focus on complicated not forms; iv) structured approach patient; v) pharmacokinetics pharmacodynamics main antimicrobial options; vi) controversies therapeutic approach. Despite ongoing efforts better stratify manage MRSA-BSI, there is no universally accepted classification system accurately distinguishing between uncomplicated/low risk complicated/high forms. Biomarkers such as interleukin(IL)-10 hold promise order enable more precise stratification, premise for an appropriate treatment plan. There theoretical rationale implementing combination therapy including beta-lactam agent upfront, especially patients considered at higher unfavorable outcomes, but further data necessary, same applies newer adjuvants. Novel microbiological techniques may help guiding duration.

Language: Английский

---

Ceftobiprole mono-therapy versus combination or non-combination regimen of standard antibiotics for the treatment of complicated infections: A systematic review and meta-analysis.

Diagnostic Microbiology and Infectious Disease, Journal Year: 2024, Volume and Issue: 109(3), P. 116263 - 116263

Published: March 16, 2024

Language: Английский

---

Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort

Antibiotics, Journal Year: 2023, Volume and Issue: 12(7), P. 1218 - 1218

Published: July 21, 2023

Ceftobiprole is a fifth-generation cephalosporin that has been approved in Europe solely for the treatment of community-acquired and nosocomial pneumonia. The objective was to analyze use ceftobiprole medocaril (Cefto-M) Spanish clinical practice patients with infections hospital or outpatient parenteral antimicrobial therapy (OPAT).This retrospective, observational, multicenter study included treated from 1 September 2021 31 December 2022.A total 249 individuals were enrolled, aged 66.6 ± 15.4 years, whom 59.4% male Charlson index four (IQR 2-6), 13.7% had COVID-19, 4.8% an intensive care unit (ICU). most frequent type infection respiratory (55.8%), followed by skin soft tissue (21.7%). Cefto-M administered 67.9% as empirical treatment, which monotherapy 7 days (5-10) 53.8% cases. infection-related mortality 11.2%. highest rates identified ventilator-associated pneumonia (40%) due methicillin-resistant Staphylococus aureus (20.8%) Pseudomonas aeruginosa (16.1%). mortality-related factors age (OR: 1.1, 95%CI (1.04-1.16)), ICU admission 42.02, (4.49-393.4)), sepsis/septic shock 2.94, (1.01-8.54)).In real life, safe antibiotic, comprising only half prescriptions infections, mainly rescue pluripathological severe infectious diseases.

Language: Английский

---

Real-life use of ceftobiprole for severe infections in a French intensive care unit

Infectious Diseases Now, Journal Year: 2023, Volume and Issue: 54(1), P. 104790 - 104790

Published: Sept. 27, 2023

Language: Английский

---

Pharmacokinetic and pharmacodynamic considerations for optimizing antimicrobial therapy used to treat bone and joint infections: an evidence-based algorithmic approach

Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2023, Volume and Issue: 19(8), P. 511 - 535

Published: Aug. 3, 2023

Introduction Bone and joint infections (BJIs) are a major health concern causing remarkable morbidity mortality. However, which antimicrobial treatment could be the best according to specific clinical scenarios and/or pharmacokinetic/pharmacodynamic (PK/PD) features remains an unmet need. This multidisciplinary opinion article aims develop evidence-based algorithms for empirical targeted antibiotic therapy of patients affected by BJIs.Areas covered A team four experts had several rounds assessment developing devoted BJIs. literature search was performed on PubMed-MEDLINE (until April 2023) provide evidence supporting therapeutic choices. Four different were structured infection types (i.e. vertebral osteomyelitis, prosthetic infections, infected non-unions other chronic infectious arthritis), need or not surgical intervention revision, isolation clinically relevant bacterial pathogens from blood tissue cultures, PK/PD antibiotics.Expert The proposed based multifaceted approach considering peculiar each (spectrum activity, properties, bone penetration rate, anti-biofilm activity), hopefully helpful in improving outcome

Language: Английский

---

Safety and effectiveness of fifth generation cephalosporins for the treatment of methicillin-resistant staphylococcus aureus bloodstream infections: a narrative review exploring past, present, and future

Expert Opinion on Drug Safety, Journal Year: 2023, Volume and Issue: 23(1), P. 9 - 36

Published: Dec. 26, 2023

Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) is a major issue in healthcare, since it often associated with endocarditis or deep site foci. Relevant morbidity and mortality MRSA-BSIs forced the development of new antibiotic strategies; particular, this review will focus attention on fifth-generation cephalosporins (ceftaroline/ceftobiprole), that are only ß-lactams active against MRSA.

Language: Английский

---